Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

PBYI Relative to the S&P 500

PBYI Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Puma Biotechnology, Inc. (NASD:PBYI) seasonal charts above shows that a Buy Date of January 1 and a Sell Date of March 22 has resulted in a geometric average return of 4.07% above the benchmark rate of the S&P 500 Total Return Index over the past 13 years. This seasonal timeframe has shown positive results compared to the benchmark in 10 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 13 years by an average of 24.33% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

To download PBYI seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: PBYI